Journal of Antivirals & Antiretrovirals
Open Access

Nanotechnology and Liposome-Based Strategies for Antiviral Drug Delivery Systems

Priya Desaii^{* *}Correspondence: Priya Desaii, Department of Biotechnology, Indian Institute of Science, Bangalore, India, Email:

Author info »

Description

The probe for effective antiviral therapies has intensified with the emergence of global viral outbreaks, highlighting the urgent need for innovative drug delivery systems. Traditional methods of antiviral administration often fall short due to issues like low bioavailability, rapid clearance, and systemic toxicity. In response, researchers are increasingly turning to advanced drug delivery technologies, particularly nanotechnology and liposomebased strategies, to enhance the efficacy of antiviral agents and improve patient outcomes. Antiviral drugs are typically administered orally or intravenously, but these methods can lead to several challenges. Poor solubility and stability in biological fluids can hinder drug absorption, while rapid metabolism may result in subtherapeutic concentrations in target tissues. Additionally, systemic toxicity can limit the dose that can be safely administered, making it difficult to achieve effective antiviral concentrations at the site of infection [1,2].

To overcome these limitations, there is a growing interest in developing novel drug delivery systems that optimize the pharmacokinetics and pharmacodynamics of antiviral agents. Nanotechnology, in particular, has emerged as a promising avenue for enhancing drug delivery through its ability to manipulate materials at the molecular and nanoscale levels. Nanotechnology offers a variety of platforms for the development of antiviral drug delivery systems, including nanoparticles, nanocarriers, and nanostructured materials. These systems can improve drug solubility, prolong circulation time, and enhance tissue targeting [3].

Nanosized particles can encapsulate antiviral drugs, protecting them from degradation and enhancing their stability. They can also be designed to release the drug in a controlled manner, ensuring sustained therapeutic levels over time [4]. For instance, lipid-based nanoparticles have been investigated for delivering RNA interference (RNAi) therapies aimed at silencing viral genes, demonstrating the potential for targeted antiviral strategies. Functionalizing nanoparticles with ligands that bind to specific receptors on infected cells allows for targeted delivery. This specificity minimizes off-target effects and increases the concentration of the drug at the site of infection, potentially improving efficacy while reducing systemic toxicity. For example, targeting CD4 receptors in HIV therapy can enhance drug uptake in infected T cells. Nanoparticles can also facilitate the cellular uptake of antiviral agents. Many viruses exploit cellular endocytosis pathways for entry, and nanocarriers can be designed to mimic viral particles, enhancing their internalization. This can lead to increased intracellular concentrations of the antiviral drug, improving therapeutic outcomes [5,6].

Liposomes are lipid-based nanocarriers that encapsulate drugs within a phospholipid bilayer, offering a versatile platform for drug delivery. Their biocompatibility and ability to encapsulate both hydrophilic and hydrophobic drugs make them particularly appealing for antiviral applications. Liposomes can be engineered to release their payload in response to specific stimuli, such as pH or temperature changes, which is particularly useful for targeting viral infections that occur in distinct tissue environments. For instance, liposomes can be designed to release their antiviral content in the acidic microenvironment of tumor cells or during viral entry. By encapsulating antiviral drugs within liposomes, researchers can improve the stability and bioavailability of these compounds. This is especially important for drugs that are prone to degradation in the gastrointestinal tract or blood circulation. Liposomal formulations of existing antiviral drugs have demonstrated improved pharmacokinetics and enhanced therapeutic effects in preclinical studies. Liposomes can also be used to deliver combination therapies, wherein multiple antiviral agents are encapsulated together. This approach can target different stages of the viral life cycle, potentially overcoming resistance mechanisms. For example, using liposomes to deliver both an antiviral and an immunemodulating agent may synergistically enhance antiviral effects and promote a robust immune response [7].

The application of nanotechnology and liposome-based strategies in antiviral drug delivery is already showing promise in clinical settings. Several liposomal formulations of antiviral drugs, such as amphotericin B and zidovudine, have been approved for clinical use, demonstrating improved safety profiles and therapeutic efficacy [8]. Looking ahead, ongoing research is focused on optimizing these delivery systems for a broader range of antiviral agents, including those targeting emerging viral infections such as SARS-CoV-2 and various influenza strains. The integration of advanced imaging techniques and biomarkerguided approaches may further enhance the precision of these delivery systems, enabling personalized treatment regimens. Despite the potential of nanotechnology and liposome-based strategies, several challenges remain. Manufacturing scalability, regulatory hurdles, and long-term safety assessments are important factors that need to be addressed. Additionally, the potential for immune responses against nanoparticles must be carefully evaluated to prevent adverse effects [9].

Moreover, while these advanced delivery systems show promise in enhancing the efficacy of antiviral therapies, they should be viewed as complementary to existing treatment strategies. A holistic approach that combines innovative delivery methods with conventional antiviral drugs, vaccines, and supportive care will be essential in managing viral infections effectively. Antiviral drug delivery systems leveraging nanotechnology and liposomebased strategies represent a significant advancement in the management of viral infections. By enhancing drug stability, improving bioavailability, and enabling targeted delivery, these innovations hold the potential to transform antiviral therapy. As research continues to evolve, the integration of these advanced delivery systems into clinical practice may lay foundation for more effective and personalized antiviral treatments, ultimately improving outcomes for patients worldwide. The future of antiviral therapy looks promising, driven by the power of technology and innovative thinking [10].

References

1. Rojekar S, Gholap AD, Togre N, Bhoj P, Haeck C, Hatvate N, et al. Current status of mannose receptor-targeted drug delivery for improved anti-HIV therapy. J Control Release. 2024;372:494-521.

   [Crossref] [Google Scholar] [PubMed]

2. Poonia N, Jadhav NV, Mamatha D, Garg M, Kabra A, Bhatia A, et al. Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia. Ther Deliv. 2024;15(11):893-910.

   [Crossref] [Google Scholar] [PubMed]

3. Chen X, Liu S, Chen M, Ni N, Zhou R, Wang Y, et al. Novel therapeutic perspectives for wet age-related macular degeneration: RGD-modified liposomes loaded with 2-deoxy-D-glucose as a promising nanomedicine. Biomed Pharmacother. 2024;175:116776.

   [Crossref] [Google Scholar] [PubMed]

4. Chaturvedi A, Sharma S, Shukla R. Drug nanocrystals: A delivery channel for antiviral therapies. AAPS PharmSciTech. 2024;25(3):41.

   [Crossref] [Google Scholar] [PubMed]

5. Shafai NME, Mostafa YS, Ramadan MS, Mehasseb IME. Enhancement efficiency delivery of antiviral molnupiravir-drug via the loading with self-assembly nanoparticles of pycnogenol and cellulose which are decorated by zinc oxide nanoparticles for COVID-19 therapy. Bioorg Chem. 2024;143:107028.

   [Crossref] [Google Scholar] [PubMed]

6. Charitidis FT, Adabi E, Ho N, Braun A, Tierney C, Strasser L, et al. Car gene delivery by t-cell targeted lentiviral vectors is enhanced by rapamycin induced reduction of antiviral mechanisms. Adv Sci (Weinh). 2023;10(35):e2302992.

   [Crossref] [Google Scholar] [PubMed]

7. Rues P, Guthmann H, Uhlig N, Agbaria M, Issmail L, Eberlein V, et al. Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system. J Control Release. 2023 Dec:364:654-671.

   [Crossref] [Google Scholar] [PubMed]

8. Megantara S, Rusdin A, Budiman A, Shamsuddin S, Mohtar N, Muchtaridi M. Revolutionizing antiviral therapeutics: unveiling innovative approaches for enhanced drug efficacy. Int J Nanomedicine. 2024;19:2889-2915.

   [Crossref] [Google Scholar] [PubMed]

9. Wu L, Qiao L, Zhang S, Qiu J, Du Z, Sun Y, et al. Dual-engineered macrophage-microbe encapsulation for metastasis immunotherapy. Adv Mater. 2024;36(36):e2406140.

   [Crossref] [Google Scholar] [PubMed]

10. Chheda D, Shete S, Tanisha T, Bahadure SD, Sampathi S, Junnuthula V, et al. Multifaceted therapeutic applications of biomimetic nanovaccines. Drug Discov Today. 2024;29(6):103991.

    [Crossref] [Google Scholar] [PubMed]